Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18992998 | 0.89 | HSP90AA1 (0.41) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29658586 | 0.88 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL12043978 | 0.88 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1057433 | 0.88 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29433057 | 0.86 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13167710 | 0.86 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL10819613 | 0.86 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16756072 | 0.86 | NR1H2 (0.52) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29262901 | 0.85 | PIK3CD (0.43) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1056456 | 0.85 | NR1H2 (0.46) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| EP-3329919-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1707566-A1 | Deazapurines and uses thereof | Eisai Co., Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2004063336-A2 | USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS | EISAI CO. LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | PIK3CD 1107/4885ABL1 2310/4885EGFR 3657/4885 |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | PIK3CD 2949/4885ABL1 1319/4885EGFR 3471/4885 |
| US-20050124649-A1 | Deazapurines and uses thereof | TPMT, CD38, CD2 | PIK3CD 2922/4885ABL1 1396/4885EGFR 3535/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | PIK3CD 1107/4885ABL1 2310/4885EGFR 3657/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | PIK3CD 1107/4885ABL1 2310/4885EGFR 3657/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | PIK3CD 2770/4885ABL1 1375/4885EGFR 4514/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | PIK3CD 1107/4885ABL1 2310/4885EGFR 3657/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | PIK3CD 2205/4885ABL1 2796/4885EGFR 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.